ArticleJournal of gastroenterology2025
Diagnostic performance of attenuation imaging versus controlled attenuation parameter for hepatic steatosis with MRI-based proton density fat fraction as the reference standard: a prospective multicenter study.
Article in Journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic performance of ultrasound attenuation imaging in detecting hepatic steatosis.Journal of medical ultrasonics (2001) · 2026Pooled it
- Effect of region of interest settings on diagnostic performance of attenuation imaging in hepatic steatosis.Journal of medical ultrasonics (2001) · 2026Article
- Non-invasive imaging diagnostic techniques in metabolic dysfunction-associated steatotic liver disease: a roadmap for clinicians.Hormones (Athens, Greece) · 2026Review
- Multiparametric Ultrasound Assessment of Long-Term Liver Damage in COVID-19: Results of a Three-Year Follow-Up Study.Medicina (Kaunas, Lithuania) · 2026Article
- Correlation of ultrasound attenuation with proton density fat fraction across multiple organs in healthy volunteers.Medical physics · 2026Article
- Current Trends and Perspectives on Obesity and Metabolic Dysfunction-Associated Steatohepatitis in East Asia.Journal of obesity & metabolic syndrome · 2026Review
- Reliability of liver stiffness measurements using shear wave elastography: impact of skin-to-capsule distance and subcutaneous tissue structure.Journal of medical ultrasonics (2001) · 2026Article
- Ultrasound Attenuation Coefficient as a Biomarker of Hepatic Steatosis: State of the Art and Software Evaluation.Journal of clinical medicine · 2026Review
- Beyond biochemistry: multiparametric ultrasound parameters and their molecular correlates in cardio-renal-metabolic syndrome.Acta biochimica Polonica · 2026Review
- Era of metabolic dysfunction-associated steatotic liver disease and impact on the liver donor pool.World journal of gastroenterology · 2025Review
- A framework of biomarkers for adipose tissue aging: a consensus statement by the Aging Biomarker Consortium.Life medicine · 2025Article
- Sex Differences in MASLD After Age 50: Presentation, Diagnosis, and Clinical Implications.Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAttenuation Imaging (ATI) and controlled attenuation parameter (CAP) are non-invasive ultrasound-based methods for diagnosing hepatic steatosis. However, reports on the clinical usefulness of ATI are limited. We aimed to compare the ability of ATI and CAP to diagnose hepatic steatosis with magnetic resonance imaging-based proton density fat fraction (MRI-PDFF) as the reference standard.
methodsWe performed a prospective multicenter study of 562 patients with chronic liver disease who underwent ATI, CAP, and MRI-PDFF. Patients with skin-to-liver capsule distance (SCD) ≤ 25 mm underwent CAP with an M probe; those with SCD > 25 mm underwent CAP with an XL probe. MRI-PDFF was used as the reference standard: S0 corresponds to MRI-PDFF < 5.2%, S1 to 5.2% ≤ MRI-PDFF < 11.3%, S2 to 11.3% ≤ MRI-PDFF < 17.1%, and S3 to MRI-PDFF ≥ 17.1%.
resultsThe correlation coefficients for ATI and MRI-PDFF stratified by body mass index (< 30, ≥ 30 kg/m
conclusionsATI is a more useful non-invasive method for diagnosing hepatic steatosis than CAP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.